Representative Matters
REFERENZMANDATE
代表事项
Public Company Transactions
- Foundation Medicine, in its (i) $120 million initial public offering, (ii) collaboration and equity transaction with Roche, with total value in excess of $1 billion and (iii) sale of the remaining minority interest to Roche for $2.4 billion
- Ocera Therapeutics, in its (i) acquisition by Mallickrodt for up to $117 million in upfront cash and contingent (CVR) consideration, (ii) $28 million PIPE financing, (iii) $25 million public offering and (iv) $25 million “at the market” offering facility
- Allena Pharmaceuticals in its $75 million initial public offering
- Chiasma in its $102 million initial public offering
- J.P. Morgan in a $200 million convertible note offering of Intrexon
- J.P. Morgan and Barclays Capital in the $184 million initial public offering of Intrexon
- J.P. Morgan and BofA Merrill Lynch in the $116 million follow-on offering of Intrexon
- JMP Securities in the $230 million follow-on offering of Intrexon
- Cantor Fitzgerald in a $200 million “at the market” offering facility for Intrexon
- Vivo Capital in investments in BioPharmX, Strongbridge Pharma, Kadmon and MEI Pharma
- Intralinks, Tranzyme and Tengion in their initial public offerings
Mergers and Acquisitions
- Aspire Health in its acquisition by Anthem
- Orchard Platform in its acquisition by Kabbage
- Glossier in its acquisition of Dynamo E-Media
- Thar Pharmaceuticals in its acquisition by Grünenthal
- Songza in its acquisition by Google
- M5 Networks in its acquisition by ShorTel
- XGraph in its acquisition by Add This (formerly Clearspring)
- Fidelis Security Systems in its acquisition by General Dynamics
- Nomi Technologies in its acquisition by Brickstream
- Tagman in its acquisition by Ensighten
- EveryScreen Media in acquisition by Media6Degrees
Private Financings
- Glossier in various financings with participation by Institutional Venture Partners, Thrive Capital, Forerunner Ventures and Index Ventures
- Hubble Contacts in various financings with participation by First Mark Capital, Two River, Wildcat Capital Management, Founders Fund, Greycroft and Colgate
- Aircall in various financings with participation by Draper Esprit, Next World Capital, Balderton Capital and eFounders
- Codiak BioSciences in various financings with participation by ARCH Venture Partners, Flagship Pioneering, Fidelity, Alaska Permanent Fund, Alexandria Venture Investments, Qatar Investment Authority, Tavistock Group, Sirona Capital, EcoR1 Capital and Casdin Capital
- Celtra in various financings with participation by WPP, Unilever, Grandbanks Capital and Fairhaven Capital
- Syntimmune in its $50.0 million financing led by Apple Tree Partners
- PatientBank in its $2.2 million financing led by General Catalyst and Khosla Ventures with participation by SV Angels, Spectrum 28 and Data Collective
- Allena Pharmaceuticals in its $53 million financing led by Partner Fund Management, Fidelity and Wellington
- Precision Biologics in its $50 million financing by NantWorks
- Orchard Platform in its $30 million financing led by Thrive Capital, Spark Capital and Canaan Partners
- Linkwell Health in various financings with participation by HLM Venture Partners and Spark Capital
- Even Financial in its $2.8 million financing led by Canaan Partners and Lerer Hippeau Ventures
- Pond5 in its $61 million financing by Accel Partners and Stripes Group
- Paperless Post in its $25 million financing led by August Capital
- Megaphone TV in its $4.3 million financing led by Softbank Korea
- Nomi Technologies in its $10 million financing by Accel Partners, First Round Capital, Greycroft and Forerunner Ventures
- Glasswing Ventures as lead investor in an $8.3 million financing of Talla
- InterWest and Orbimed, as lead investors, in a $32 million investment in Avedro
- Hermed Capital in its investments in Prognos and Spineology
Professional Activities
Mr. Lang is a frequent lecturer at the Cardozo Tech Law Start Up Clinic, Columbia Business School, Columbia Law School, Cornell Tech and eLab NYC on venture financings and other elements of start-up law.